AR089143A1 - Triazolopiridinas sustituidas con actividad inhibidora de ttk - Google Patents
Triazolopiridinas sustituidas con actividad inhibidora de ttkInfo
- Publication number
- AR089143A1 AR089143A1 ARP120104640A ARP120104640A AR089143A1 AR 089143 A1 AR089143 A1 AR 089143A1 AR P120104640 A ARP120104640 A AR P120104640A AR P120104640 A ARP120104640 A AR P120104640A AR 089143 A1 AR089143 A1 AR 089143A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- compounds
- hydrogen atom
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos intermediarios útiles para preparar dichos compuestos. Reivindicación 1: Un compuesto de la fórmula general (1) en donde: R¹ representa un resto de fórmula (2) donde * indica el punto de unión de dicho grupo con el resto de la molécula; R² representa un resto de fórmula (3) donde * indica el punto de unión de dicho grupo con el resto de la molécula; R³ representa un átomo de hidrógeno; R⁴ representa un átomo de hidrógeno; R⁵ representa un átomo de hidrógeno o un grupo alquilo C₁₋₃; R⁵ᵃ representa un grupo seleccionado entre: -alcoxi C₁₋₄-, halo-alcoxi C₁₋₄-, alquilo C₁₋₄; R⁵ᵇ representa un grupo seleccionado entre: -C(=O)N(H)R⁸, -C(=O)NR⁸R⁷, -N(R⁷)C(=O)OR⁸, R⁷-S(=O)₂-; R⁶ representa un grupo de fórmula (4); donde * indica el punto de unión de dicho grupo con el resto de la molécula; donde dicho grupo está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un átomo de halógeno o un grupo metilo; R⁷ representa un grupo alquilo C₁₋₃ o un ciclopropilo; R⁸ representa un átomo de hidrógeno o un grupo alquilo C₁₋₆ o cicloalquilo C₃₋₆, donde dicho grupo alquilo C₁₋₆ o cicloalquilo C₃₋₆ está opcionalmente sustituido, una o más veces, con un átomo de halógeno; o R⁷ y R⁸ junto con el fragmento molecular al que se unen representan un anillo heterocíclico de entre 4 y 6 miembros, que está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un átomo de halógeno, un grupo alquilo C₁₋₃, halo-alquilo C₁₋₃ o alcoxi C₁₋₃; R⁹ representa un grupo seleccionado entre: alquilo C₁₋₃, hidroxi-alquilo C₁₋₃, -N(H)R⁸, -N(R⁷)R⁸, N(H)(R⁸)-alquilo C₁₋₃, N(R⁷)(R⁸)-alquilo C₁₋₃; y Q representa CH o N; o un tautómero, un N-óxido, un hidrato, un solvato o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193011 | 2011-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089143A1 true AR089143A1 (es) | 2014-07-30 |
Family
ID=47427291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104640A AR089143A1 (es) | 2011-12-12 | 2012-12-11 | Triazolopiridinas sustituidas con actividad inhibidora de ttk |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9663510B2 (es) |
| EP (1) | EP2791136B1 (es) |
| JP (1) | JP6181664B2 (es) |
| KR (1) | KR20140105552A (es) |
| CN (1) | CN104114552B (es) |
| AP (1) | AP4017A (es) |
| AR (1) | AR089143A1 (es) |
| AU (1) | AU2012350751B2 (es) |
| BR (1) | BR112014014184A2 (es) |
| CA (1) | CA2858683A1 (es) |
| CL (1) | CL2014001546A1 (es) |
| CO (1) | CO6980657A2 (es) |
| CR (1) | CR20140275A (es) |
| CU (1) | CU20140068A7 (es) |
| CY (1) | CY1116958T1 (es) |
| DK (1) | DK2791136T3 (es) |
| DO (1) | DOP2014000133A (es) |
| EC (1) | ECSP14004812A (es) |
| ES (1) | ES2550677T3 (es) |
| GT (1) | GT201400111A (es) |
| HR (1) | HRP20151103T1 (es) |
| HU (1) | HUE025937T2 (es) |
| IL (1) | IL232930A (es) |
| JO (1) | JO3111B1 (es) |
| MA (1) | MA35826B1 (es) |
| MX (1) | MX2014007057A (es) |
| PE (1) | PE20141597A1 (es) |
| PH (1) | PH12014501319A1 (es) |
| PL (1) | PL2791136T3 (es) |
| PT (1) | PT2791136E (es) |
| RS (1) | RS54288B1 (es) |
| RU (1) | RU2632464C1 (es) |
| SG (1) | SG11201402820SA (es) |
| SI (1) | SI2791136T1 (es) |
| TN (1) | TN2014000254A1 (es) |
| UA (1) | UA112096C2 (es) |
| UY (1) | UY34515A (es) |
| WO (1) | WO2013087579A1 (es) |
| ZA (1) | ZA201404031B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015000308A2 (pt) * | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | método para preparo de triazolopiridinas substituídas |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| PE20160156A1 (es) * | 2013-06-11 | 2016-04-20 | Bayer Pharma AG | Derivados de prodroga de triazolpiridinas sustituidas |
| EP3007692A1 (en) * | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| WO2015176981A1 (en) * | 2014-05-19 | 2015-11-26 | Basf Se | Fluorescent organic light emitting elements having high efficiency |
| MA41136A (fr) * | 2014-12-09 | 2017-10-17 | Bayer Pharma AG | Composés pour le traitement d'un cancer |
| EP3233127A1 (de) | 2014-12-15 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern |
| CN105985241A (zh) * | 2015-01-27 | 2016-10-05 | 邵阳学院 | α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用 |
| AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
| JP2018525334A (ja) | 2015-06-23 | 2018-09-06 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| TW201800408A (zh) | 2016-06-15 | 2018-01-01 | 拜耳製藥公司 | Mps-1抑制劑 |
| WO2018077944A2 (en) * | 2016-10-27 | 2018-05-03 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| CN106831555B (zh) * | 2017-01-22 | 2019-09-24 | 中国农业大学 | 吡啶酰胺类化合物及其制备方法与应用 |
| KR102668688B1 (ko) | 2018-07-23 | 2024-05-24 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CA3128946A1 (en) | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
| KR102661468B1 (ko) | 2019-02-15 | 2024-04-30 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 전자 장치 |
| KR102897919B1 (ko) | 2019-11-14 | 2025-12-09 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 장치 |
| WO2023167549A1 (en) * | 2022-03-04 | 2023-09-07 | Sillajen, Inc. | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6693116B2 (en) * | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| JP4499721B2 (ja) | 2003-06-30 | 2010-07-07 | ヒフ バイオ，インク． | 化合物、組成物および方法 |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| ES2549862T3 (es) | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| EP2178868A1 (en) | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| MX2010002312A (es) | 2007-08-31 | 2010-03-18 | Merck Serono Sa | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2222674B8 (en) | 2007-11-27 | 2016-01-06 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| CN102317288A (zh) | 2009-02-13 | 2012-01-11 | 佛维雅制药公司 | 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶 |
| ES2547328T3 (es) | 2009-04-29 | 2015-10-05 | Bayer Intellectual Property Gmbh | Imidazoquinoxalinas sustituidas |
| JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| AU2011206635B2 (en) | 2010-01-15 | 2015-01-22 | Cellzome Limited | Novel substituted triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| JP2011246389A (ja) * | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体 |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| US20140120087A1 (en) * | 2011-04-21 | 2014-05-01 | Bayer Intellectual Property Gmbh | Triazolopyridines |
-
2012
- 2012-10-12 UA UAA201407687A patent/UA112096C2/uk unknown
- 2012-12-10 CN CN201280069310.8A patent/CN104114552B/zh not_active Expired - Fee Related
- 2012-12-10 US US14/362,836 patent/US9663510B2/en not_active Expired - Fee Related
- 2012-12-10 PT PT128055167T patent/PT2791136E/pt unknown
- 2012-12-10 HU HUE12805516A patent/HUE025937T2/en unknown
- 2012-12-10 HR HRP20151103TT patent/HRP20151103T1/hr unknown
- 2012-12-10 PE PE2014000944A patent/PE20141597A1/es not_active Application Discontinuation
- 2012-12-10 JP JP2014546446A patent/JP6181664B2/ja not_active Expired - Fee Related
- 2012-12-10 KR KR1020147019041A patent/KR20140105552A/ko not_active Withdrawn
- 2012-12-10 EP EP12805516.7A patent/EP2791136B1/en active Active
- 2012-12-10 PL PL12805516T patent/PL2791136T3/pl unknown
- 2012-12-10 SG SG11201402820SA patent/SG11201402820SA/en unknown
- 2012-12-10 DK DK12805516.7T patent/DK2791136T3/en active
- 2012-12-10 CA CA2858683A patent/CA2858683A1/en not_active Abandoned
- 2012-12-10 MX MX2014007057A patent/MX2014007057A/es unknown
- 2012-12-10 WO PCT/EP2012/074978 patent/WO2013087579A1/en not_active Ceased
- 2012-12-10 AP AP2014007731A patent/AP4017A/en active
- 2012-12-10 RS RS20150663A patent/RS54288B1/sr unknown
- 2012-12-10 BR BR112014014184A patent/BR112014014184A2/pt not_active Application Discontinuation
- 2012-12-10 SI SI201230337T patent/SI2791136T1/sl unknown
- 2012-12-10 AU AU2012350751A patent/AU2012350751B2/en not_active Ceased
- 2012-12-10 ES ES12805516.7T patent/ES2550677T3/es active Active
- 2012-12-10 RU RU2014128465A patent/RU2632464C1/ru not_active IP Right Cessation
- 2012-12-11 AR ARP120104640A patent/AR089143A1/es unknown
- 2012-12-11 JO JOP/2012/0375A patent/JO3111B1/ar active
- 2012-12-12 UY UY0001034515A patent/UY34515A/es not_active Application Discontinuation
-
2014
- 2014-06-02 IL IL232930A patent/IL232930A/en not_active IP Right Cessation
- 2014-06-03 ZA ZA2014/04031A patent/ZA201404031B/en unknown
- 2014-06-10 PH PH12014501319A patent/PH12014501319A1/en unknown
- 2014-06-10 MA MA37115A patent/MA35826B1/fr unknown
- 2014-06-11 TN TNP2014000254A patent/TN2014000254A1/en unknown
- 2014-06-12 DO DO2014000133A patent/DOP2014000133A/es unknown
- 2014-06-12 CO CO14127883A patent/CO6980657A2/es unknown
- 2014-06-12 EC ECIEPI20144812A patent/ECSP14004812A/es unknown
- 2014-06-12 CR CR20140275A patent/CR20140275A/es unknown
- 2014-06-12 GT GT201400111A patent/GT201400111A/es unknown
- 2014-06-12 CU CU2014000068A patent/CU20140068A7/es unknown
- 2014-06-12 CL CL2014001546A patent/CL2014001546A1/es unknown
-
2015
- 2015-10-23 CY CY20151100951T patent/CY1116958T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| AR089550A1 (es) | Compuestos quimicos | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094100A1 (es) | DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR100776A1 (es) | Compuestos herbicidas | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |